NovaBridge Biosciences logo
NovaBridge Biosciences
NBP | NASDAQ
Chart Builder DCF Calculator
$0.79
-$0.06 (-7.05%)
At close: Nov 16, 2026, 4:00 PM ET
$0.79
$0.00 (-0.06%)
After-hours: Nov 16, 2026, 7:30 PM ET

NovaBridge Biosciences Company Profile

Company profile explained

Company Profile

NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.

Key Executives

Name Position
Srishti Gupta Chief Executive Officer & Director
Ming Lei Chief Financial Officer
Cong Xu Executive VP and Head of R&D Center of Excellence
Liwei Lin General Counsel & Board Secretary
Mark Hagler President & Chief Commercial Officer
Phillip Dennis Chief Medical Officer
Sean Wuxiong Cao Chief Business Development Officer & Director
Tyler Ehler Senior Director of Investor Relations
Wei Fu Executive Chairman

Latest SEC Filings

Date Type Title
Oct 28, 2026 6-K Filing
Oct 26, 2026 6-K Filing
Oct 23, 2026 6-K Filing
Oct 19, 2026 4 Filing
Oct 13, 2026 6-K Filing
Sep 21, 2026 4 Filing
Sep 11, 2026 4 Filing
Sep 10, 2026 3 Filing
Sep 08, 2026 4 Filing
Sep 08, 2026 6-K Filing
View All SEC Filings ➞
NovaBridge Biosciences
NovaBridge Biosciences logo
Country United States
IPO Date Jan 17, 2020
Industry Biotechnology
Sector Healthcare
Employees 30
CEO Srishti Gupta

Contact Details

2440 Research Boulevard Rockville, Maryland 20850 United States

Stock Details

Ticker Symbol NBP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001778016
CUSIP Number 44975P103
ISIN Number US44975P1030
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.